EXR
57
-2
QCOM
48
-7
HRL
39
15
DNB
78
6
DE
46
3
NWSA
62
2
EXC
54
-2
URI
53
-2
AKAM
43
3
VLO
40
-2
HON
65
-2
ILMN
32
-3
XEL
67
2
EIX
77
2
KMX
58
3
TAP
58
-2
PDCO
35
-3
DVA
72
2
WDC
41
-2
OXY
40
3
EXR
57
-2
QCOM
48
-7
HRL
39
15
DNB
78
6
DE
46
3
NWSA
62
2
EXC
54
-2
URI
53
-2
AKAM
43
3
VLO
40
-2
HON
65
-2
ILMN
32
-3
XEL
67
2
EIX
77
2
KMX
58
3
TAP
58
-2
PDCO
35
-3
DVA
72
2
WDC
41
-2
OXY
40
3
Financhill
Back

Aligos Therapeutics 10K Form

Buy
55

ALGS
Aligos Therapeutics

Last Price:
18.29
Seasonality Move:
0%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ALGS News And Ratings

See the #1 stock for the next 7 days that we like better than ALGS

ALGS Financial Statistics

Sales & Book Value

Annual Sales: $15.53M
Cash Flow: $-20.13M
Price / Cash Flow: 0
Annual Sales: $15.07
Price / Book: 1.44

Profitability

EPS (TTM): -17.10530
Net Income (TTM): $-76.95M
Gross Margin: --
Return on Equity: -118.75%
Return on Assets: -68.4%

Aligos Therapeutics Earnings Forecast

Key Aligos Therapeutics Financial Ratios

  • The Research & Development expenses have been 470.35% of Revenue.
  • The Net Earning history of ALGS is -564.61% of Total Revenues.
  • Per Share Earnings over the last 5 years have been positive in 3 years.

Aligos Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ALGS
Website: aligos.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.81
Quick Ratio: 3.58

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ALGS Technical Analysis vs Fundamental Analysis

Buy
55
Aligos Therapeutics (ALGS) is a Buy

Is Aligos Therapeutics a Buy or a Sell?